Bayer Racks Kerendia Win in Subgroup Analysis

A narrowly missed primary endpoint didn’t prevent Bayer from touting a phase 3 win for Kerendia (finerenone) as a cardioprotective agent for people with late-stage chronic kidney disease and type 2 diabetes.
Source: Drug Industry Daily